Skip to main content
Figure 5 | Journal of Translational Medicine

Figure 5

From: Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma

Figure 5

HGF release correlates with disease burden and with IDO activity in patients with MM. HGF levels were measured with ELISA both in PB and BM fluid of patients with MGUS, SMM and symptomatic MM at different ISS stages (panels A-D). HGF levels in patients and controls were compared with the Kruskal-Wallis test for unpaired determinations with Dunns correction for multiple comparisons. Bars depict median values and inter-quartile ranges. Panel E: HGFA in PB and BM fluid was measured in patients with MM using commercially available ELISA kits. Comparisons were performed with the Kruskal-Wallis test for unpaired determinations with Dunns correction for multiple comparisons. Panel F: HGF levels in the BM microenvironment were correlated with IDO activity, as expressed in terms of KYN release into the systemic circulation. When MM patients were dichotomized based on KYN levels (<1.8 μM or >1.8 μM), KYNhi patients released significantly higher levels of HGF compared with KYNlo patients. Comparisons were performed with the Kruskal-Wallis test for unpaired determinations with Dunns correction for multiple comparisons. Panel G: Disease burden, HGF release, KYN and tryptophan levels were measured in 1 patient with MM, both before (disease onset) and after treatment (T1 and T2 = 6 months and 1 year, respectively, after chemotherapy with bortezomib, melphalan and prednisone). The percentage of malignant PC as well as serum levels of M-component progressively declined, in correlation with serum and BM HGF, and with KYN.

Back to article page